DNA

Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, United Kingdom and NEW YORK, January 7, 2026 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing…

4 weeks ago

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a…

4 weeks ago

CellRight Tech: Private Equity Funding Secured

SAN ANTONIO, TX / ACCESS Newswire / January 7, 2026 / CellRight Technologies, LLC, a specialist in regenerative allografts for…

4 weeks ago

Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insightsSAN DIEGO, Jan. 6,…

4 weeks ago

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in…

4 weeks ago

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology…

4 weeks ago

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and…

4 weeks ago

Weight Watchers Expands Its Integrated GLP-1 Platform with Access to Wegovy® Pill Advancing a New Standard for Long-Term Weight Health

A NovoCare® Recognized Care Provider, Weight Watchers’ new Med+ program delivers an integrated GLP-1 care model proven to drive greater…

4 weeks ago

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

BETHLEHEM, Pa., Jan. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) (“OraSure” and “OTI”), a leader in point-of-need…

4 weeks ago

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

4 weeks ago